Dopamine metabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Dopamine metabolic process pathway differs between tumor and matched normal tissue in 13 of the 18 cancer types tested.

The strongest signal is observed in lung adenocarcinoma (LUAD), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUAD and LUSC, show the opposite pattern, with lower activity in tumor tissue.

LUAD, LUSC, and LIHC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.054	<.001	9	view →
LUSC	All	III,IV	−0.094	<.001	8	view →
LIHC	Female	All	−0.077	<.001	8	view →
HNSC	Male	II,III,IV	−0.034	<.001	8	view →
UCEC	All	All	−0.064	<.001	6	view →
KIRP	All	II,III,IV	−0.059	.003	6	view →
BRCA	All	All	−0.046	<.001	6	view →
BLCA	Male	All	−0.045	.002	5	view →
KICH	Female	All	−0.071	<.001	4	view →
CHOL	Male	All	−0.125	<.001	3	view →
THCA	Female	All	−0.018	<.001	3	view →
KIRC	Female	IV	−0.036	.037	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 13 lineages.

GO:0042417–LUAD

Open the LUAD breakdown →